中文

Journal of Shanghai University >

2019 , Vol. 25 >Issue 3: 357 - 364

DOI: https://doi.org/10.12066/j.issn.1007-2861.2135

Research Progress on ischemic heart disease and energy metabolism

Expand
  • Beijing Key Laboratory of Cardiovascular Receptors Research. Beijing 100191, China.Ischemia heart disease changes in cardiac energy metabolism, which contributes to contractile dysfunction and a decrease in cardiac efficiency. Specific metabolic changes include a relative increase in cardiac fatty acid oxidation rates and an uncoupling of glycolysis from glucose oxidation. Recent evidence suggests that therapeutically regulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation can improve cardiac function of the ischaemic heart. With the development of metabolomics technology, the detection methods and mechanisms of early metabolites for ischemic cardiomyopathy are further explored. we review the change of energy metabolic which contributing to cardiac dysfunction, and then it explores the potential for targeting treatment ischemic heart disease through metabolic pathway.

Received date: 2019-04-10

  Online published: 2019-06-24

Fold

Abstract

Ischemia heart disease is often accompanied by cardiac energy metabolism, which is reflected in contractile dysfunction and a decrease in cardiac efficiency. Specific metabolic changes include a relative increase in cardiac fatty acid oxidation rates and an uncoupling of glycolysis from glucose oxidation. Recent evidence suggests that therapeutically regulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation can improve cardiac function of the ischemic heart. With the development of metabolomics technology, the detection methods and mechanisms of early metabolites for ischemic cardiomyopathy are further explored. This paper first discusses systematically the change of energy metabolic which contributes to cardiac dysfunction, and then it explores the potential for targeting treatment ischemic heart disease through metabolic pathway.

Key words： Key Words：Ischemia heart disease; fatty acid oxidation; metabolism

Cite this article

Zhang Jianshu, Xu Ming . Research Progress on ischemic heart disease and energy metabolism[J]. Journal of Shanghai University, 2019 , 25(3) : 357 -364 . DOI: 10.12066/j.issn.1007-2861.2135

References

[1] Fillmore N, Levasseur J L, Fukushima A , et al. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction[J]. Mol Med, 2018,24(1):3.
[2] Fillmore N, Mori J, Lopaschuk G D . Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy[J]. Br J Pharmacol, 2014,171(8):2080-2090.
[3] Stanley W C, Recchia F A, Lopaschuk G D . Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 2005,85(3):1093-1129.
[4] McGarrah R W, Crown S B, Zhang G F , et al. Cardiovascular metabolomics[J]. Circ Res, 2018,122(9):1238-1258.
[5] Lopaschuk G D, Ussher J R, Folmes C D , et al. Myocardial fatty acid metabolism in health and disease[J]. Physiol Rev, 2010,90(1):207-258.
[6] Chouchani E T, Pell V R, Gaude E , et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS[J]. Nature, 2014,515(7527):431-435.
[7] Yue T L, Bao W, Jucker B M , et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury[J]. Circulation, 2003,108(19):2393-2399.
[8] Liu Z, Chen J M, Huang H , et al. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway[J]. Metabolism, 2016,65(3):122-130.
[9] Killalea S M, Krum H . Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease[J]. Am J Cardiovasc Drugs, 2001,1(3):193-204.
[10] Dyck J R, Cheng J F, Stanley W C , et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation[J]. Circ Res, 2004,94(9):e78-e84.
[11] Sun W, Liu Q, Leng J , et al. The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases[J]. Life Sci, 2015,121:97-103.
[12] Li X, Liu J, Hu H , et al. Dichloroacetate ameliorates cardiac dysfunction caused by ischemic insults through AMPK signal pathway-not only shifts metabolism[J]. Toxicol Sci, 2019,167(2):604-617.
[13] Ussher J R, Wang W, Gandhi M , et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury[J]. Cardiovasc Res, 2012,94(2):359-369.
[14] Folmes C D, Sowah D, Clanachan A S , et al. High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency[J]. J Mol Cell Cardiol, 2009,47(1):142-148.
[15] Hooper L, Martin N, Abdelhamid A , et al. Reduction in saturated fat intake for cardiovascular disease[J]. Cochrane Database Syst Rev, 2015 (6): CD011737.
[16] Wang D D, Li Y, Chiuve S E , et al. Association of specific dietary fats with total and cause-specific mortality[J]. JAMA Intern Med, 2016,176(8):1134-1145.
[17] Gonzalez-Rodriguez A, Mayoral R, Agra N , et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD[J]. Cell Death Dis, 2014,5:e1179.
[18] van de Weijer T, Schrauwen-Hinderling V B, Schrauwen P . Lipotoxicity in type 2 diabetic cardiomyopathy[J]. Cardiovasc Res, 2011,92(1):10-18.
[19] Holland W L, Summers S A . Strong heart, low ceramides[J]. Diabetes, 2018,67(8):1457-1460.
[20] Laaksonen R, Ekroos K, Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016,37(25):1967-1976.
[21] Souza-Mello V . Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease[J]. World J Hepatol, 2015,7(8):1012-1019.
[22] Dezsi C A . Trimetazidine in practice: review of the clinical and experimental evidence[J]. Am J Ther, 2016,23(3):e871-e879.
[23] Danchin N, Marzilli M, Parkhomenko A , et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis[J]. Cardiology, 2011,120(2):59-72.
[24] Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina [J]. Cochrane Database Syst Rev, 2005 (4): CD003614.
[25] Zhao Q, Cui Z, Zheng Y , et al. Fenofibrate protects against acute myocardial I/R injury in rat by suppressing mitochondrial apoptosis as decreasing cleaved caspase-9 activation[J]. Cancer Biomark, 2017,19(4):455-463.
[26] Bukhari I A, Almotrefi A A, Mohamed O Y , et al. Protective effect of fenofibrate against ischemia-/reperfusion-induced cardiac arrhythmias in isolated rat hearts[J]. Fundam Clin Pharmacol, 2018,32(2):141-146.
[27] Lam V H, Zhang L, Huqi A , et al. Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts[J]. Circ Res, 2015,117(1):41-51.
[28] Jaswal J S, Keung W, Wang W , et al. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart[J]. Biochim Biophys Acta, 2011,1813(7):1333-1350.
[29] Yamauchi T, Nio Y, Maki T , et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions[J]. Nature Medicine, 2007,13:332.
[30] Knottnerus S J G, Bleeker J C, Wust R C I , et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle[J]. Rev Endocr Metab Disord, 2018,19(1):93-106.
[31] Mallet R T, Squires J E, Bhatia S , et al. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium[J]. Journal of Molecular and Cellular Cardiology, 2002,34(9):1173-1184.
[32] Wolff A A, Rotmensch H H, Stanley W C , et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective[J]. Heart Failure Reviews, 2002,7(2):187-203.
[33] Ussher J R, Koves T R, Jaswal J S , et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking Malonyl CoA Decarboxylase[J]. Diabetes, 2009,58(8):1766-1775.
[34] Mdaki K S, Larsen T D, Wachal A L , et al. Maternal high-fat diet impairs cardiac function in offspring of diabetic pregnancy through metabolic stress and mitochondrial dysfunction[J]. Am J Physiol Heart Circ Physiol, 2016,310(6):H681-H692.
[35] Vlassara H, Uribarri J . Advanced glycation end products (AGE) and diabetes: cause, effect, or both?[J]. Curr Diab Rep, 2014,14(1):453.
[36] Mizushima N, Yoshimori T, Ohsumi Y . The role of Atg proteins in autophagosome formation[J]. Annu Rev Cell Dev Biol, 2011,27:107-132.
[37] Ruiz-Canela M, Toledo E, Clish C B , et al. Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial[J]. Clinical Chemistry, 2016,62(4):582-592.
[38] Lu G, Sun H, She P , et al. Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells[J]. J Clin Invest, 2009,119(6):1678-1687.
[39] Newgard C B . Interplay between lipids and branched-chain amino acids in development of insulin resistance[J]. Cell Metab, 2012,15(5):606-614.
[40] Crowe M J, Weatherson J N, Bowden B F . Effects of dietary leucine supplementation on exercise performance[J]. Eur J Appl Physiol, 2006,97(6):664-672.
[41] D'Antona G, Ragni M, Cardile A, et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice[J]. Cell Metab, 2010,12(4):362-372.
[42] Li T, Zhang Z, Kolwicz S C, Jr ., et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury[J]. Cell Metab, 2017,25(2):374-385.
Options
Outlines

/

〈 〉